Skip to content
Medical Health Aged Care

Cleo Diagnostics Enhances Board Capacity

Cleo Diagnostics Limited ASX.COV 2 mins read

MELBOURNE, AUSTRALIA, 2 October, 2023: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) confirms current Chief Scientific Officer and Executive Director, Dr Andrew Stephens, role will move to full-time effective 1 October, 2023.

Following the Company’s successful listing on the ASX in August, Dr Andrew Stephens has agreed to expand his commitment to the Company by moving his Chief Scientific Officer and Executive Director responsibilities to full-time, up from three days per week part-time. All remaining terms and conditions of Dr Stephens employment agreement are unchanged.

The enhancement to Cleo’s Board capacity is designed to direct clear executive focus on the Company’s phased development strategy to deliver a simple and accurate blood test capable of detecting ovarian cancer at every stage.

Commenting on the enhanced Board capacity, CLEO Chief Executive, Richard Allman, said:
“It is pleasing to see Dr Stephens expand his time commitment to Cleo which will effectively allow the Company to step up our ability to execute on our development program and strategy.  It also further reinforces the confidence and conviction Cleo has in bringing our cancer diagnostics technology to market as soon as possible.”

Dr Andrew Stephens, added:
“The urgency to address the global unmet meet for accurate and early diagnosis of ovarian cancer is clear.  I look forward to dedicating my focus full-time alongside the Board, my colleagues, and partners to advance Cleo’s ambition to address ovarian cancer through a simple and accurate blood test.


About us:

About Cleo DIagnostics

CleoDX aims to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease.  The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, Cleo has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests. 

The clinical unmet worldwide need is urgent. An accurate and early detection blood test could shift survivability for ovarian cancer significantly as seen with other cancers. Cleo is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

Contact details:

Elvis Jurcevic
Investor Relations
+61 408 268 271

More from this category

  • Medical Health Aged Care
  • 07/12/2023
  • 23:07
Moderna, Inc.

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event

The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to employees and communitiesCAMBRIDGE, MA / ACCESSWIRE / December 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will provide an update on its Environmental, Social and Governance (ESG) strategy at its second ESG Investor Event. Building off its inaugural ESG Day in November 2022, the Company will highlight the year's progress on its ESG journey and future work to further impact global health and protect the environment."Our mRNA platform science has benefited patients around the world and with that comes great responsibility…

  • Medical Health Aged Care
  • 07/12/2023
  • 13:30
Royal Australian College of GPs and Australian College of Rural and Remote Medicine

Public consultation on Rural Generalist Medicine recognition closes next Tuesday

With less than one week to go until the public consultation closes on recognition of Rural Generalist Medicine (RGM) as a specialist field, Australia’s two GP colleges urge doctors and community members to have their say. The Australian College of Rural and Remote Medicine (ACRRM) and the Royal Australian College of General Practitioners (RACGP) are buoyed by the conversation that has been generated on the recognition of RGM throughout the process. ACRRM President Dr Dan Halliday says it has been wonderful to see the engagement through the recent webinars hosted by the Rural Generalist Taskforce, through College channels and at…

  • Contains:
  • Medical Health Aged Care, Science
  • 07/12/2023
  • 13:26
The Florey

Researchers identify neurons in the brain that control nasofacial muscles during breathing

Whilst most of us consider breathing a relatively simple process, it actually requires complex coordination of many muscles to enable airflow into and out of the lungs and to control airflow to allow us to talk, eat, and drink. Breathing also influences other related brain functions, such as emotional state, sense of smell, blood pressure, and heart rate. Breathing is generated in a brain region called Pre-Bötzinger complex (preBötC), which is composed of many subgroups of neurons that are breathing and non-breathing related. Up to now, due to technical limitations, it was almost impossible to specifically silence a subgroup of…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.